[1]Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424.
[2]Roth MY, Witt RL, Steward DL. Molecular testing for thyroid nodules: Review and current state[J]. Cancer, 2018,124(5):888-898.
[3]Jin Y, Van Nostrand D, Cheng L, et al. Radioiodine refractory differentiated thyroid cancer[J]. Crit Rev Oncol Hematol, 2018,125:111-120.
[4]Ulitsky I, Bartel DP. lincRNAs: genomics, evolution, and mechanisms[J]. Cell, 2013,154(1):26-46.
[5]Rinn JL. lncRNAs: linking RNA to chromatin[J]. Cold Spring Harb Perspect Biol, 2014,6(8):a018614
[6]Xu H, Yang X, Huang W, et al. Singlecell profiling of long noncoding RNAs and their cell lineage commitment roles via RNADNADNA triplex formation in mammary epithelium[J]. Stem Cells, 2020. doi: 10.1002/stem.3274. Online ahead of print.
[7]Yao RW, Wang Y, Chen LL. Cellular functions of long noncoding RNAs[J]. Nat Cell Biol, 2019,21(5):542-551.
[8]Ingolia NT, Brar GA, SternGinossar N, et al. Ribosome profiling reveals pervasive translation outside of annotated proteincoding genes[J]. Cell Rep, 2014,8(5):1365-1379.
[9]Huang JZ, Chen M, Chen, et al. A peptide encoded by a putative lncRNA HOXBAS3 suppresses colon cancer growth[J]. Mol Cell, 2017,68(1):171-184.e6.
[10]Meng X, Wang H, Zhao J, et al. Apatinib inhibits cell proliferation and induces autophagy in human papillary thyroid carcinoma via the PI3K/Akt/mTOR signaling pathway[J]. Front Oncol, 2020,10:217.
[11]Zhang J, Du Y, Zhang X, et al. Downregulation of BANCR promotes aggressiveness in papillary thyroid cancer via the MAPK and PI3K pathways[J]. J Cancer, 2018,9(7):1318-1328.
[12]Chen G, Gao Y, Wang G, et al. MiR145 inhibits the migration and invasion of papillary thyroid carcinoma cells through NFκB pathway regulation[J]. J Cell Biochem, 2020,121(5-6):3325-3332.
[13]Bi CL, Zhang YQ, Li B, et al. MicroRNA520a3p suppresses epithelialmesenchymal transition, invasion, and migration of papillary thyroid carcinoma cells via the JAK1mediated JAK/STAT signaling pathway[J]. J Cell Physiol, 2019,234(4):4054-4067.
[14]Wang DP, Tang XZ, Liang QK, et al. Overexpression of long noncoding RNA SLC26A4AS1 inhibits the epithelialmesenchymal transition via the MAPK pathway in papillary thyroid carcinoma[J]. J Cell Physiol, 2020,235(3):2403-2413.
[15]Wen J, Wang H, Dong T, et al. STAT3induced upregulation of lncRNA ABHD11AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR13013p/STAT3 axis and PI3K/AKT signalling pathway[J]. Cell Prolif, 2019,52(2):e12569.
[16]Yang Z, Li G, Ding C, et al. Long noncoding RNA HULC exerts oncogenic activity on papillary thyroid cancer in vitro and in vivo[J]. Artif Cells Nanomed Biotechnol, 2020,48(1):326-335.
[17]Sun W, Qin Y, Wang Z, et al. The NEAT1_2/miR491 axis modulates papillary thyroid cancer invasion and metastasis through TGM2/NFκb/FN1 signaling[J]. Front Oncol, 2021,11:610547.
[18]Dai W, Jin X, Han L, et al. Exosomal lncRNA DOCK9AS2 derived from cancer stem celllike cells activated Wnt/βcatenin pathway to aggravate stemness, proliferation, migration, and invasion in papillary thyroid carcinoma[J]. Cell Death Dis, 2020,11(9):743.
[19]Aiello NM, Kang Y. Contextdependent EMT programs in cancer metastasis[J]. J Exp Med, 2019,216(5):1016-1026.
[20]Zhou T, Zhong M, Zhang S, et al. LncRNA CASC2 expression is downregulated in papillary thyroid cancer and promotes cell invasion by affecting EMT pathway[J]. Cancer Biomark, 2018,23(2):185-191.
[21]Wu L, Shi Y, Liu B, et al. Expression of lncRNAHOTAIR in the serum of patients with lymph node metastasis of papillary thyroid carcinoma and its impact[J]. Oncol Lett, 2020,20(1):907-913.
[22]Gao P, Jiao H, Zhe L, et al. High expression of LINC0163 promotes progression of papillary thyroid cancer by regulating epithelialmesenchymal transition MITF[J]. Eur Rev Med Pharmacol Sci, 2020,24(10):5504-5511.
[23]Liang W, Sun F. Identification of pivotal lncRNAs in papillary thyroid cancer using lncRNAmRNAmiRNA ceRNA network analysis[J]. Peer J, 2019,7:e7441.
[24]Ballantyne MD, McDonald RA, Baker AH. lncRNA/MicroRNA interactions in the vasculature[J]. Clin Pharmacol Ther, 2016,99(5):494-501.
[25]Jiang W, Zhan H, Jiao Y, et al. A novel lncRNAmiRNAmRNA network analysis identified the hub lncRNA RP11159F24.1 in the pathogenesis of papillary thyroid cancer[J]. Cancer Med, 2018,7(12):6290-6298.
[26]Xia F, Chen Y, Jiang B, et al.Long noncoding RNA HOXAAS2 promotes papillary thyroid cancer progression by regulating miR520c3p/S100A4 pathway[J].Cell Physiol Biochem,2018,50(5):1659-1672.
[27]Ding W, Zhao S, Shi Y, et al. Positive feedback loop SP1/SNHG1/miR199a5p promotes the malignant properties of thyroid cancer[J]. Biochem Biophys Res Commun, 2020,522(3):724-730.
[28]Liu H, Li R, Guan L, et al. Knockdown of lncRNA UCA1 inhibits proliferation and invasion of papillary thyroid carcinoma through regulating miR204/IGFBP5 axis[J]. Onco Targets Ther, 2018,11:7197-7204.
[29]Wang R, Zhao L, Ji L, et al. Myocardial infarction associated transcript(MIAT) promotes papillary thyroid cancer progression via sponging miR212[J]. Biomed Pharmacother, 2019,118:109298.
[30]Liu W, Wang Z, Wang C, et al. Long noncoding RNA MIAT promotes papillary thyroid cancer progression through upregulating LASP1[J]. Cancer Cell Int, 2019,19:194.
[31]Pang R, Yang S. LncRNA DUXAP8 inhibits papillary thyroid carcinoma cell apoptosis via sponging the miR20b5p/SOS1 axis[J]. Oncol Rep, 2021,45(5): 64.
[32]Liu Y, Zhang H, Wang H, et al. Long noncoding RNA DUXAP8 promotes the cell proliferation, migration, and invasion of papillary thyroid carcinoma via miR2233p mediated regulation of CXCR4[J]. Bioengineered, 2021,12(1):496-506.
[33]Qin Y, Sun W, Wang Z, et al. ATF2induced lncRNA GAS8AS1 promotes autophagy of thyroid cancer cells by targeting the miR1873p/ATG5 and miR13433p/ATG7 axes[J]. Mol Ther Nucleic Acids, 2020,22:584-600.
[34]Sun W, Yin D. Long noncoding RNA CASC7 inhibits the proliferation and migration of papillary thyroid cancer cells by inhibiting miR34a5p[J]. J Physiol Sci, 2021,71(1):9.
[35]Liu C, Feng Z, Chen T, et al. Downregulation of NEAT1 reverses the radioactive iodine resistance of papillary thyroid carcinoma cell via miR1013p/FN1/PI3KAKT signaling pathway[J]. Cell Cycle, 2019,18(2):167-203.
[36]Liu Y, Yue P, Zhou T, et al. LncRNA MEG3 enhances 131I sensitivity in thyroid carcinoma via sponging miR182[J]. Biomed Pharmacother, 2018,105:1232-1239.
[37]Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer[J]. Mol Cell Endocrinol, 2010,321(1):86-93.
[38]Gandolfi G, Sancisi V, Piana S, et al. Time to reconsider the meaning of BRAFV600E mutation in papillary thyroid carcinoma[J]. Int J Cancer, 2015,137(5):1001-1011.
[39]Zheng H, Xu J, Hao S, et al. Expression of BANCR promotes papillary thyroid cancer by targeting thyroid stimulating hormone receptor[J]. Oncol Lett, 2018,16(2):2009-2015.
[40]Wang Y, Lin X, Fu X, et al. Long noncoding RNA BANCR regulates cancer stem cell markers in papillary thyroid cancer via the RAF/MEK/ERK signaling pathway[J]. Oncol Rep, 2018,40(2):859-866.
[41]Liao T, Qu N, Shi RL, et al. BRAFactivated lncRNA functions as a tumor suppressor in papillary thyroid cancer[J]. Oncotarget, 2017,8(1):238-247.
[42]Esposito R, Esposito D, Pallante P, et al. Oncogenic properties of the antisense lncRNA COMET in BRAF and RETdriven papillary thyroid carcinomas[J]. Cancer Res, 2019,79(9):2124-2135.
[43]Zhao X, Hu X. Downregulated long noncoding RNA LINC00313 inhibits the epithelialmesenchymal transition, invasion, and migration of thyroid cancer cells through inhibiting the methylation of ALX4[J]. J Cell Physiol, 2019,234(11):20992-21004.
[44]Yang LX, Wu J, Guo ML, et al. Suppression of long noncoding RNA TNRC6CAS1 protects against thyroid carcinoma through DNA demethylation of STK4 via the Hippo signalling pathway[J]. Cell Prolif, 2019,52(3):e12564.
[45]Li Q, Wang P, Sun C, et al. Integrative analysis of methylation and transcriptome identified epigenetically regulated lncRNAs with prognostic relevance for thyroid cancer[J]. Front Bioeng Biotechnol, 2019,7:439.
[46]Gou Q, Gao L, Nie X, et al. Long noncoding RNA AB074169 inhibits cell proliferation via modulation of KHSRPmediated CDKN1a expression in papillary thyroid carcinoma[J]. Cancer Res, 2018,78(15):4163-4174.
[47]Wu T, Zhang DL, Wang JM, et al. TRIM29 inhibits miR8735P biogenesis via CYTOR to upregulate fibronectin 1 and promotes invasion of papillary thyroid cancer cells[J]. Cell Death Dis, 2020,11(9):813. |